【病例分享】第93期：尼妥珠单抗与帕博利珠单抗联合化疗用于食管癌术前新辅助治疗

(Summary description)【病例分享】第93期：尼妥珠单抗与帕博利珠单抗联合化疗用于食管癌术前新辅助治疗

Next: 【病例分享】第92期：尼妥珠单抗治疗局部复发的鼻咽癌

Next: 【病例分享】第92期：尼妥珠单抗治疗局部复发的鼻咽癌



Home
About Us 
-  About Us
- About Us
- Core Team
- Development History
- Corporate Culture
About Us
BPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
S&T 
-  S&T
- Research Areas
- Technology Platforms
S&T
The world's leading humanized monoclonal antibody preparation process and large-scale continuous mammalian cells culture technology.
Research and Development 
-  Research and Development
- Marketed Products
- R&D Products
- R&D Pipeline
- Academic Progress
Research and Development
BPL developed the first humanized monoclonal antibody drug Nimotuzumab (trade name: Taixinsheng) for the treatment of malignant tumors in China.
Media Center 
-  Media Center
- Press Releases
- Media Reports
Media Center
Present industry-related media reports and various company activities and trends.
Join Us 
-  Join Us
- Post-Doctoral Center
Join Us
We sincerely welcome talents from all walks of life to join BPL, qualified as post-doctoral research workstation with diversified professional positions.
Contact Us 
-  Contact Us
- Contact Us
Contact Us
Counseling Hotline: 400-659-2330
TEL: 010-50571020